Menu
Peptide Database
Results
No peptides found
Featured

Use search to browse all 100+ peptides

Dihexa

N-(1-Oxohexyl)-L-tyrosyl-N-(6-amino-6-oxohexyl)-L-isoleucinamide, N-hexanoic-Tyr-Ile-(6) aminohexanoic amide, PNB-0408

Quick Stats
Studies 17
Trials 0
Score 2
2014 pubmed 49 citations

The development of small molecule angiotensin IV analogs to treat Alzheimer's and Parkinson's diseases.

Wright. John W JW; Kawas. Leen H LH; Harding. Joseph W JW

Key Findings

  • AngIV works through the AT4 receptor, likely the insulin‑regulated aminopeptidase (IRAP) and may also involve the HGF/c‑Met pathway.
  • Small‑molecule AngIV analogs like Dihexa are metabolically stable, cross the blood‑brain barrier, and boost synaptic connectivity.
  • In pre‑clinical models, Dihexa improved memory and motor function by promoting the formation of new functional synapses.

Practical Outcomes

  • Dihexa is still in early research stages and not available for human use, so there’s no dosage or protocol to apply yet. However, the work suggests that targeting the AngIV/AT4 system could become a future strategy for enhancing brain health, so biohackers should keep an eye on upcoming clinical trials and safety data.

Summary

Researchers made a new, stable version of the brain peptide AngIV called Dihexa that can get into the brain and help form new synapses, which in animal studies improved memory and movement problems linked to Alzheimer’s and Parkinson’s.

Abstract

Alzheimer's (AD) and Parkinson's (PD) diseases are neurodegenerative diseases presently without effective drug treatments. AD is characterized by general cognitive impairment, difficulties with memory consolidation and retrieval, and with advanced stages episodes of agitation and anger. AD is increasing in frequency as life expectancy increases. Present FDA approved medications do little to slow disease progression and none address the underlying progressive loss of synaptic connections and neurons. New drug design approaches are needed beyond cholinesterase inhibitors and N-methyl-d-aspartate receptor antagonists. Patients with PD experience the symptomatic triad of bradykinesis, tremor-at-rest, and rigidity with the possibility of additional non-motor symptoms including sleep disturbances, depression, dementia, and autonomic nervous system failure. This review summarizes available information regarding the role of the brain renin-angiotensin system (RAS) in learning and memory and motor functions, with particular emphasis on research results suggesting a link between angiotensin IV (AngIV) interacting with the AT4 receptor subtype. Currently there is controversy over the identity of this AT4 receptor protein. Albiston and colleagues have offered convincing evidence that it is the insulin-regulated aminopeptidase (IRAP). Recently members of our laboratory have presented evidence that the brain AngIV/AT4 receptor system coincides with the brain hepatocyte growth factor/c-Met receptor system. In an effort to resolve this issue we have synthesized a number of small molecule AngIV-based compounds that are metabolically stable, penetrate the blood-brain barrier, and facilitate compromised memory and motor systems. These research efforts are described along with details concerning a recently synthesized molecule, Dihexa that shows promise in overcoming memory and motor dysfunctions by augmenting synaptic connectivity via the formation of new functional synapses.

Study Information

Provider

pubmed

Year

2014

Date

2014-11-29T00:00:00.000Z

DOI

10.1016/j.pneurobio.2014.11.004

Citations

49

References

384